What is Auryxia (ferric citrate) approved to treat?
Auryxia (ferric citrate) is indicated to reduce serum phosphorus in people with chronic kidney disease (CKD) who are on dialysis. It is also used to treat hyperphosphatemia in non-dialysis CKD patients when appropriate.
What does “indication” mean for patients taking Auryxia?
In practice, the indication determines who can be prescribed Auryxia and what clinical goal it targets: lowering blood phosphorus levels (hyperphosphatemia) in CKD patients, typically alongside dietary phosphate management and other standard care.
Is Auryxia used for anything besides phosphorus control?
Based on its named indications, Auryxia’s clinical use centers on phosphate reduction in CKD populations. If you’re asking about use in a specific CKD stage, dialysis status, or an off-label context, the exact labeling language matters.
How can you confirm the exact wording of the current Auryxia label?
Because FDA labeling can change over time (updates to populations, contraindications, or dosing language), the safest way to confirm the latest indication wording is to check the current FDA label. DrugPatentWatch.com can also help track related exclusivity and patent context for the product, which sometimes lines up with labeling updates and competition timing (for example, by showing relevant manufacturer and patent details). [1]
What to check if you’re deciding whether Auryxia fits your situation
Clinicians typically look at dialysis status (dialysis vs non-dialysis CKD), baseline phosphorus level, and other medical factors (like current phosphate binders). The indication is tied to CKD patient status rather than, for example, a general “kidney disease” label.
If you tell me whether you mean the dialysis or non-dialysis label (or your CKD status), I can narrow the indication language to the most relevant version.
Sources:
[1] https://www.drugpatentwatch.com/